Hemophilia, Levin, Vertex, Semma & More
Summary
This race has been in the making for decades, and runs through the highs and lows of the gene therapy field—from its enormous promise, to the safety issues that eviscerated investment in the field many years ago.—Jeremy Levin, the former Bristol-Myers Squibb dealmaker and Teva Pharmaceutical CEO, is back; he’s become the chairman of a New York startup called Ovid Therapeutics, which is developing treatments for orphan diseases of the brain.—Shares of Waltham, MA-based ImmunoGen (NASDAQ: IMGN) surged over 20 percent on Monday after the firm cut a $440 million deal with Takeda to develop cancer drugs using its antibody-drug conjugate technology.—Cambridge-based Semma Therapeutics emerged from stealth with a bang: a $44 million Series A round from MPM Capital, Fidelity Biosciences, Arch Venture Partners, and Medtronic, and an undisclosed deal with Novartis.Vertex had said previously that the data from the study were good enough to move VX-661 into Phase 3 testing, but as TheStreet.com and Bloomberg wrote this week, the numbers fell short of expectations.
Classifications
AskAI Classifications
LabelsLinked Companies
